text
"['\n2. 주요 제품 및 서비스\n가. 주요제품 매출\n(단위 : 백만원, %)\n사업부문\n매출유형\n품\xa0\xa0 목\n구체적용도\n주요상표등\n제9기 3분기\n제8기\n제7기\n매출액\n비율\n매출액\n비율\n매출액\n비율\n의약품 등\n제품\n그로트로핀\n성장호르몬\n-\n32,105\n7.29\n32,452\n\xa05.53\xa0\n24,568\n\xa04.01\xa0\n모티리톤\n기능성소화불량제\n-\n23,232\n5.28\n29,026\n\xa04.95\xa0\n27,095\n\xa04.43\xa0\n슈가논\n당뇨병치료제\n-\n23,091\n5.24\n23,757\n\xa04.05\xa0\n14,193\n2.32\xa0\n가스터\n소화성궤양치료제\n-\n21,391\n4.86\n22,320\n\xa0 3.81\xa0\n16,690\n\xa02.73\xa0\n주블리아\n손발톱무좀치료제\n-\n21,309\n4.84\n22,267\n\xa0 3.80\xa0\n8,210\n\xa02.97\xa0\n오팔몬\n허혈성개선제\n-\n17,195\n3.91\n23,178\n\xa0 3.95\xa0\n24,867\n\xa04.06\xa0\n플라비톨\n항혈전제\n-\n15,960\n3.62\n18,785\n\xa03.20\xa0\n19,420\n3.17\xa0\n스티렌\n위점막보호제\n-\n14,620\n3.32\n20,869\n\xa0 3.56\xa0\n20,421\n\xa03.34\xa0\n리피논\n고지혈증치료제\n-\n12,853\n2.92\n14,343\n\xa02.45\xa0\n15,544\n\xa02.54\xa0\n이달비\n고혈압치료제\n-\n7,759\n1.76\n9,550\n\xa0 1.63\xa0\n8,168\n\xa01.33\xa0\n바라클\nB형간염치료제\n-\n5,471\n1.24\n6,961\n\xa0 1.19\xa0\n5,818\n\xa00.95\xa0\n상품\n캔박카스\n에너지드링크\n-\n59,827\n13.59\n82,146\n14.00\xa0\n90,518\n14.78\xa0\n기타\n-\n-\n-\n185,490\n42.13\n280,918\n47.89\xa0\n326,737\n53.37\xa0\n합계\n-\n-\n-\n-\n440,303\n100.00\n586,572\n100.00\xa0\n612,249\n100.00\n나. 주요제품 가격변동추이\n(단위 : 원)\n구\xa0 분\n제9기 3분기\n제8기\n제7기\n전문의약품\n스티렌(1Tab)\n112\n112\n112\n리피논(20㎎. 1Tab)\n682\n682\n682\n플라비톨(1Tab)\n1,153\n1,153\n1,153\n모티리톤(1Tab)\n152\n152\n152\n슈가논(1Tab)\n737\n737\n737\n(1) 산출기준- 전문의약품 : 보험약가 기준(2) 주요 가격변동 원인- 전문의약품 : 선별등재시스템(PLS), 특허만료의약품 약가인하, 일괄약가인하, 사용량 약가연동제 등 정부의 약가인하 정책에 따른 가격통제를 받음\n']"
